Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems (NYSE: VEEV) has announced it will release its financial results for the fourth quarter and full fiscal year 2025, which ended January 31, 2025, after market close on March 5, 2025. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results.
Prepared remarks will be posted to Veeva's investor relations website approximately one hour before the call. A webcast replay will be available following the live event.
Veeva Systems (NYSE: VEEV) announced that over 200 companies, including 17 of the top 20 biopharmas, are now using Veeva CTMS for clinical trial management. The platform helps streamline trial processes and enhance collaboration as studies become more complex and data-intensive.
The system serves as a central hub for managing study metrics and documents, enabling both insourced and outsourced trial operations while maintaining compliance with global regulations like ICH E6(R2) and (R3). New features include automated CRO-to-sponsor data transfers, improved oversight issue tracking, and enhanced capabilities for managing complex trials.
Veeva CTMS is part of the broader Veeva Clinical Platform, designed to accelerate trial execution and improve operational efficiency. The company continues to enhance the platform through three product releases annually.
Veeva Systems (NYSE: VEEV) and Zifo announced a product partnership aimed at modernizing quality control operations in biopharma. The integration combines Veeva LIMS with Zifo's data integration platform, qcKen, enabling direct data import from any source document or other LIMS systems.
The partnership will simplify master data configuration during LIMS implementation and site deployment, helping companies transition from legacy QC systems. The collaboration focuses on streamlining test and specification data creation, expediting implementation processes, and delivering faster ROI for new Veeva LIMS customers.
As part of the agreement, Zifo becomes an official Veeva Product Partner, expanding their existing relationship as a Veeva Services Partner. The integration aims to support GMP quality business processes with greater accuracy while helping organizations increase scale and speed batch release cycles.
Veeva Systems (NYSE: VEEV) has announced its participation in the 27th Annual Needham Growth Conference. The company will be represented by Brian Van Wagener, CFO, and Paul Shawah, EVP Strategy, who are scheduled to present on Thursday, January 16, 2025, at 1:30 p.m. Eastern Time.
The presentation will be accessible via webcast, with both live and archived versions available on Veeva's investor relations website at https://ir.veeva.com.
Veeva Systems (NYSE: VEEV) announced growing adoption of Veeva Compass Patient, their anonymous patient longitudinal data solution. The platform provides unlimited access to daily data, covering both retail and specialty brands, helping commercial teams optimize patient journey analysis, market sizing, and field force activation.
The Compass data network encompasses over 300 million U.S. patients, 3+ million healthcare providers and clinicians, 80+ billion prescription and medical records, and more than seven years of patient history. Bayer has implemented the solution across multiple brands, reporting enhanced ability to identify HCPs and patients compared to traditional sources.
The Veeva Compass Suite includes Prescriber and National modules, offering projected prescriptions and procedures data at various levels, and is part of the broader Veeva Data Cloud platform.
Veeva Systems (NYSE: VEEV) has announced the latest release of Vault CRM Suite, featuring the new Vault CRM Campaign Manager. This integrated solution connects sales, marketing, and medical teams on a unified platform, enabling streamlined customer engagement. The system operates from a single database with shared data and content, facilitating coordinated multichannel campaigns.
Over 30 companies are currently using Vault CRM, with seven migrations from Veeva CRM scheduled for completion this month. A major global top 20 biopharma company plans to migrate more than 15,000 users to Vault CRM by the end of 2025. The suite includes Vault CRM Service Center for inside sales and contact center operations, released in August.
Veeva Systems (NYSE: VEEV) has announced its participation in the upcoming Raymond James 2024 TMT and Consumer Conference in New York. Brian Van Wagener, CFO, and Paul Shawah, EVP Strategy, will deliver a presentation on Wednesday, December 11, 2024, at 10:40 a.m. Eastern Time.
The presentation will be accessible via webcast, with both live and archived versions available on Veeva's investor relations website at https://ir.veeva.com.
Veeva Systems reported strong fiscal 2025 third quarter results with total revenues of $699.2 million, up 13% year over year, and subscription services revenues of $580.9 million, up 17% year over year. The company's operating income increased 41% to $181.4 million, while non-GAAP operating income rose 30% to $304.0 million.
Net income grew 37% to $185.8 million, with fully diluted earnings per share of $1.13. The company achieved significant milestones in its CRM business, with over 30 customers now using Vault CRM and seven migrations on track for completion. Veeva's Quality Suite applications reached over 600 customers. The company provided Q4 guidance with expected revenues between $696-699 million and updated FY2025 total revenue guidance to $2,722-2,725 million.
Veeva Systems released findings from their 2024 MedTech Commercial Benchmark survey, revealing that nearly 70% of medtech organizations still use manual processes for managing commercial content and claims. Only 15% of organizations have streamlined processes with centralized data repositories. The survey of over 130 commercial medtech leaders highlighted that 80% are pursuing content personalization strategies, while 40% lack Digital Asset Management systems. 60% of companies using manual processes experience approval times exceeding four weeks, with assets requiring 3-5 review rounds. Additionally, 45% of organizations view content creation as AI's most significant potential contribution.
Veeva Systems announced two new GenAI capabilities for Vault CRM: CRM Bot and Voice Control. CRM Bot integrates large language models into Vault CRM for tasks like pre-call planning, suggested actions, and recommended content. Voice Control enables hands-free CRM operation through Apple Intelligence. Both features are planned for late 2025 release and will be included in Vault CRM at no additional charge. These innovations are part of Veeva's broader AI strategy, which includes the Vault Direct Data API and Veeva AI Partner Program to facilitate AI integration in life sciences.
FAQ
What is the current stock price of Veeva Sys (VEEV)?
What is the market cap of Veeva Sys (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
